GLPwatch
Bydureon vs Trulicity
Drug comparison
Last updated 2026-05-28 15:46 UTCBydureon (exenatide by AstraZeneca) and Trulicity (dulaglutide by Eli Lilly) are both injectable medications for type 2 diabetes, but Trulicity is also approved to reduce cardiovascular risk. Both are taken as weekly shots under the skin, though they use different active ingredients—exenatide for Bydureon and dulaglutide for Trulicity.
AI summary of the sources below.
| Bydureon | Trulicity | |
|---|---|---|
| Active ingredient | exenatide | dulaglutide |
| Manufacturer | astrazeneca | eli-lilly |
| Route | subcutaneous injection | subcutaneous injection |
| FDA-approved for | type 2 diabetes | type 2 diabetes, cardiovascular risk reduction |
| Label updated | — | 2023-08-05 |